AstraZeneca PLC has advanced its efforts in the machine learning and artificial intelligence space by linking up with the UK's BenevolentAI in a pact it hopes will lead to new drugs for chronic kidney disease and idiopathic pulmonary fibrosis.
In an interview with Scrip, Mene Pangalos, head of R&D biopharmaceuticals at AstraZeneca, said that as part of an initiative for future growth known as AZ2025, the company has been...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?